View the latest news and SEC filings
Scroll to
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 30, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 30, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 30, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 30, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
April 2, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
March 20, 2024 |
An annual report to security holders |
ARS |
Annual Filings |
|
|
March 20, 2024 |
Official notification to shareholders of matters to be brought to a vote (“Proxy”) |
DEF 14A |
Proxy Filings |
|
|
March 12, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
|
March 8, 2024 |
A preliminary proxy statement providing notification matters to be brought to a vote |
PRE 14A |
Proxy Filings |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
